Metagenomi Therapeutics (MGX) Net Shares Issued and Repurchased (2024 - 2026)

Metagenomi Therapeutics (MGX) has reported Net Shares Issued and Repurchased for 3 consecutive years, with $692.0 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Net Shares Issued and Repurchased fell 99.36% year-over-year to $692.0 in Q1 2026; TTM through Mar 2026 was $692.0, a 99.36% decrease from a year earlier, with the FY2025 full-year figure at $87250.0, up 7.38% from the prior year.
• Net Shares Issued and Repurchased was $692.0 for Q1 2026 at Metagenomi Therapeutics, down from $87250.0 in the prior quarter.
• Over five years, Net Shares Issued and Repurchased peaked at $108089.0 in Q1 2025 and troughed at $692.0 in Q1 2026.
• A 3-year average of $68244.2 and a median of $81250.0 in 2024 frame the typical range for Net Shares Issued and Repurchased.
• Across the five-year window, Net Shares Issued and Repurchased soared 69.05% in 2025 and sank 99.36% in 2026, its largest moves.
• Over 3 years, Net Shares Issued and Repurchased stood at $81250.0 in 2024, then increased by 7.38% to $87250.0 in 2025, then slumped by 99.21% to $692.0 in 2026.
• The last three Net Shares Issued and Repurchased figures came in at $692.0 (Q1 2026), $87250.0 (Q4 2025), and $108089.0 (Q1 2025), per Business Quant data.